Beauty Health (NASDAQ:SKIN) Stock Rating Lowered by Zacks Research

Beauty Health (NASDAQ:SKIN) was downgraded by analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a note issued to investors on Wednesday,Zacks.com reports.

Other equities analysts have also issued reports about the company. Wall Street Zen cut Beauty Health from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Stifel Nicolaus upped their target price on Beauty Health from $3.00 to $4.00 and gave the company a “hold” rating in a research note on Friday, August 1st. Cowen reaffirmed a “hold” rating on shares of Beauty Health in a research report on Monday, September 22nd. TD Cowen boosted their price target on shares of Beauty Health from $2.00 to $2.50 and gave the company a “hold” rating in a report on Monday, September 22nd. Finally, Roth Capital assumed coverage on shares of Beauty Health in a research note on Friday, September 19th. They issued a “buy” rating and a $3.50 price objective for the company. One equities research analyst has rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $2.81.

Beauty Health Trading Down 2.3%

Shares of SKIN stock opened at $1.26 on Wednesday. The firm has a market capitalization of $160.65 million, a P/E ratio of -5.73 and a beta of 1.19. Beauty Health has a 1 year low of $0.78 and a 1 year high of $2.69. The firm’s fifty day simple moving average is $1.64 and its 200 day simple moving average is $1.76. The company has a current ratio of 4.98, a quick ratio of 4.07 and a debt-to-equity ratio of 5.53.

Beauty Health (NASDAQ:SKIN) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.01). The company had revenue of $70.66 million during the quarter, compared to analyst estimates of $68.33 million. Beauty Health had a negative return on equity of 19.70% and a negative net margin of 3.87%. Beauty Health has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that Beauty Health will post -0.25 EPS for the current year.

Institutional Investors Weigh In On Beauty Health

Institutional investors and hedge funds have recently made changes to their positions in the company. Prescott Group Capital Management L.L.C. increased its position in shares of Beauty Health by 47.0% during the 1st quarter. Prescott Group Capital Management L.L.C. now owns 646,798 shares of the company’s stock worth $867,000 after purchasing an additional 206,798 shares in the last quarter. Nuveen LLC bought a new stake in Beauty Health during the first quarter worth about $59,000. AQR Capital Management LLC acquired a new stake in shares of Beauty Health during the first quarter worth approximately $40,000. Goldman Sachs Group Inc. raised its stake in shares of Beauty Health by 5.0% in the first quarter. Goldman Sachs Group Inc. now owns 665,706 shares of the company’s stock valued at $892,000 after acquiring an additional 31,880 shares during the last quarter. Finally, SCS Capital Management LLC bought a new position in shares of Beauty Health in the first quarter valued at approximately $67,000. Institutional investors and hedge funds own 93.26% of the company’s stock.

Beauty Health Company Profile

The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health.